CAIX PET/CT for Residual or Recurrent Post-ablative ccRCC
{ "89Zr-Girentuximab PET/CT for Kidney Cancer", "This study is investigating if a special type of scan, called 89Zr-Girentuximab PET/CT, can help doctors see if clear cell renal cell carcinoma (ccRCC), a type of kidney cancer, is still present or has returned after treatment. Researchers want to know if this scan can detect cancer left behind or that has come back, and how the scan results change before and after standard cryoablation treatment. You may be eligible if you are 18 years or older and provide informed consent. The study plans to enroll 10 participants. The success of the study will be measured by specific values (SUVmean and SUVmax) from the PET scans of the treated area and healthy kidney tissue.", "design": "This is an interventional study with an unclear phase, planning to enroll 10 participants. It involves two groups (arms) of participants.", "commitments": "Participants in both arms will receive an injection of 89Zr-Girentuximab and have a PET scan 3-7 days later. Participants in arm 2 will also have a repeat PET scan within 3 days after their standard cryoablation treatment.", "compensation": "Not stated in the trial record.", "follow_up": "The primary endpoints are measured from enrollment to 0-3 days after standard of care cryoablation.", }
- Study design
- Not specified.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Not specified.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
CAIX PET/CT for Residual or Recurrent Post-ablative ccRCC
At a glance
Conditions
NCT07077083
Where you'd take part
This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
Massachusetts General Hospital
Boston, Massachusettsstudy coordinator listed
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- Shadi Abdar Esfahani, MD, MPH · PRINCIPAL_INVESTIGATOR · Massachusetts General Hospital
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- SUVmean of the ablated zone and adjacent or contralateral uninvolved kidneyFrom enrollment to 0-3 days after SOC cryoablation
Qualitative and quantitative assessment of 89Zr-girentuximab probe uptake of the ablative zone in the kidney will be performed. Guided by the findings of standard CT or MRI, a region of interest (ROI) will be drawn over the ablation zone and adjacent uninvolved kidney. SUVmean of the ROIs will be measured for the recurrent/residual tumor and the adjacent or contralateral normal kidney. Descriptive statistics including the mean SUVmean and standard deviation will be reported for each ROI. Tumor to kidney uptake ratio will also be calculated. It is expected that the recurrent/residual tumor will show uptake above the uninvolved kidney.
- SUVmax of the ablated zone and adjacent or contralateral uninvolved kidneyFrom enrollment to 0-3 days after SOC cryoablation
Qualitative and quantitative assessment of 89Zr-girentuximab probe uptake of the ablative zone in the kidney will be performed. Guided by the findings of standard CT or MRI, a region of interest (ROI) will be drawn over the ablation zone and adjacent uninvolved kidney. SUVmax of the ROIs will be measured for the recurrent/residual tumor and the adjacent or contralateral normal kidney. Descriptive statistics including the SUVmax and standard deviation will be reported for each ROI. Tumor to kidney uptake ratio will also be calculated. It is expected that the recurrent/residual tumor will show uptake above the uninvolved kidney.